Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

High activity of mitoxantrone in previously untreated low-grade lymphomas

  • 14 Accesses

  • 14 Citations


A consecutive series of 21 previously untreated patients with low-grade non-Hodgkin lymphomas were treated with mitoxantrone 5 mg/m2 daily for 3 days every 3 weeks. The cumulative dose did not exceed 165 mg/m2 in any patient. In this group, 7 patients had small lymphocytic lymphomas, 10 patients had follicular small cleaved cell lymphomas, and 4 patients had follicular mixed small-and large-cell lymphomas. Of the 21 patients, 20 obtained remission (complete in 6, partial in 14), and 15 of these are still in remission. Relapse-free survival is 68% at 2 years. None of the patients has died. Nonhematologic toxicity was modest. No severe alopecia was seen, and only 6 patients had nausea and vomiting (WHO grade 1–3). No cardiac toxicity was seen. In conclusion, mitoxantrone is a highly active and well-tolerated drug in this subset of patients. Hematologic toxicity, especially leukopenia, was dose limiting, and a reduction of the dose was necessary in 15 out of the 21 patients.

This is a preview of subscription content, log in to check access.


  1. 1.

    Coltman CA Jr, Coltman TM, Balcerzak SP, Morrison FS, Von Hoff DD (1984) Mitoxanthrone in refractory non-Hodgkin's lymphoma: a Southwest Oncology Group Study. Semin Oncol 11 [Suppl 1]: 50–53

  2. 2.

    Ezdinli EZ, Anderson JR, Melvin F, Glick JH, Davis TE, O'Connell MJ (1985) Moderate versus aggressive chemotherapy of nodular poorly differentiated lymphoma. J Clin Oncol 3: 769–775

  3. 3.

    Gallagher CJ, Gregory WM, Jones AE, Stansfeld AG, Richards MA, Dhaliwal HS, Malpas JS, Lister TA (1986) Follicular lymphoma. Prognostic factors for response and survival. J Clin Oncol 4: 1470–1480

  4. 4.

    Gams RA, Keller JW, Golomb HM, Steinberg J, Dukart G (1983) Mitoxanthrone in malignant lymphomas. Cancer Treat Rev 10 [Suppl B]: 69–72

  5. 5.

    Gams RA, Steinberg J, Posner L (1984) Mitoxantrone in malignant lymphoma. Semin Oncol 11 [Suppl 1]: 47–49

  6. 6.

    Jones SE, Fuks Z, Bull M, Kadin ME, Dorfman RF, Kaplan HS, Rosenberg SA, Kim H (1973) Non-Hodgkin lymphoma IV. Clinicopathologic correlation in 405 cases. Cancer 31: 806–823

  7. 7.

    Peterson BA, Frizzera G, Anderson JR, Bloomfield CD, Pajak TF, Gottlieb AJ, Holland JF (1985) Response of low grade lymphomas to cyclophosphamide (CTX) or cyclophosphamide, adriamycin, vincristine, prednisone, and belomycin (CAVPB). Proc ASCO 4: C-822

  8. 8.

    Smith IE (1983) Mitoxantrone (Novantrone): a review of experimental and early clinical studies. Cancer Treat Rev 10: 103–115

  9. 9.

    Valdivieso M, Bedikian AY, Burgess MA, Savaraj N, Jeffers WB, Bodey GP (1981) Phase I clinical study of dihydroxyanthracenedione administered on a 5-day IV schedule. Cancer Treat Rep 65: 841–844

  10. 10.

    Van Echo DA, Whitacre MY, Aisner J, Wiernik PH (1981) Phase I trial of dihydroxyanthracenedione. Cancer Treat Rep 65: 831–834

  11. 11.

    Von Hoff DD, Pollard E, Kuhn J, Murray E, Coltman CA Jr (1980) Phase I clinical investigation of 1,4-dihydroxy-5,8-bis[(2-(2-hydroxyethyl)amino]ethyl)amino)-9,10-anthracenedione dihydroxychloride (NSC 301739), a new anthracenedione. Cancer Res 40: 1516–1518

  12. 12.

    World Health Organization (1979) Handbook for reporting results of cancer treatment. WHO, Geneva (WHO offset publication no. 48)

Download references

Author information

Correspondence to Nis I. Nissen.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hansen, S.W., Nissen, N.I., Hansen, M.M. et al. High activity of mitoxantrone in previously untreated low-grade lymphomas. Cancer Chemother. Pharmacol. 22, 77–79 (1988). https://doi.org/10.1007/BF00254186

Download citation


  • Lymphoma
  • Cell Lymphoma
  • Cumulative Dose
  • Alopecia
  • Mitoxantrone